REGN News and Press, Regeneron Pharmaceuticals Inc.

2024-06-30 09:00:00 ET Summary VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for ...

2024-06-28 08:39:53 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Tran...

TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conferenc...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...

A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...

2024-06-25 09:00:09 ET Jasper Hellweg from Argus Research issued a price target of $1,170.00 for REGN on 2024-06-25 08:11:00. The adjusted price target was set to $1,170.00. At the time of the announcement, REGN was trading at $1063.89. The overall price target consensus...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $118.11 on volume of 457,565,587 shares Agrify Corporation (AGFY) rose 68.7% to $0.4251 on volume of 291,898,257 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 13.7% to $0.3662 on volume...

A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...

2024-06-20 23:47:38 ET Summary Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly boost Nektar's prospects (and share price), but Phas...